Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

    • BlueRock

    - PMLiVE

    Lilly and MeiraGTx partner in $475m ophthalmology deal

    The companies will develop and commercialise therapies for genetic conditions

    - PMLiVE

    BMS acquires Orbital Therapeutics in $1.5bn deal

    The deal includes several next-gen cell therapy candidates for autoimmune diseases

    Bayer symbol

    Bayer’s Kerendia granted FDA approval for new heart failure indication

    Approximately 55% of the 6.7 million adults in the US with HF have an LVEF of at least 40%

    The (clinical) trials and tribulations of gene therapy – why meaningful patient engagement strategies matter

    By Sarah Mohamad and Lauren Coleman-Bennett

    Amiculum

    Bayer symbol

    Bayer’s Vitrakvi receives full FDA approval for NTRK gene fusion-positive tumours

    The US regulator first approved the TRK inhibitor in 2018 under its accelerated approval pathway

    What do people look for in gene therapy materials? Results from our survey of patients and relatives

    By Sam Fraser

    Amiculum

    - PMLiVE

    FDA grants RMAT designation to AskBio’s Parkinson’s gene therapy candidate

    The progressive neurodegenerative disease affects more than ten million people worldwide

    - PMLiVE

    CSL Behring announces four-year results for haemophilia B gene therapy Hemgenix

    The genetic bleeding disorder affects an estimated one per every 19,283 male births in the US

    - PMLiVE

    NICE approves Vertex’s Casgevy one-time gene therapy for sickle cell disease

    About 15,000 people in England are living with the inherited blood disorder

    Bayer symbol

    Bayer UK launches digital educational hub to improve menopause support

    An estimated 13 million women in the UK are currently perimenopausal or menopausal

    Bayer symbol

    Bayer’s non-hormonal menopause drug shows promise in phase 3 breast cancer trial

    Breast cancer patients can experience vasomotor symptoms as a result of adjuvant endocrine therapy

    - PMLiVE

    Roche expands cell therapy capabilities with $1.5bn Poseida acquisition

    The deal includes a BCMA-targeting allogeneic CAR-T therapy candidate for multiple myeloma

    Subscribe to our email news alerts

    Latest content

    Latest intelligence

    Quick links